1. Yamamoto JF, Goodman MT: Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008, 19:379-390.
2. Schlenk RF, Dohner H: Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2013, 2013:324-330.
3. Khera N, Martin P, Edsall K, Bonagura A, Burns LJ, Juckett M, King O, LeMaistre CF, Majhail NS: Patient-centered care coordination in hematopoietic cell transplantation. Blood Adv 2017, 1:1617-1627.
4. Yang X, Wang J: Precision therapy for acute myeloid leukemia. J Hematol Oncol 2018, 11:3.
5. Kayser S, Levis MJ: Advances in targeted therapy for acute myeloid leukaemia. British Journal of Haematology 2018, 180:484-500.
6. Andresen V, Gjertsen BT: Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia: Limitations and Possibilities in the Age of Precision Therapy. Cancer J 2019, 25:153-163.
7. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ, Jr., Laird PW, et al: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013, 368:2059-2074.
8. Audia JE, Campbell RM: Histone Modifications and Cancer. Cold Spring Harb Perspect Biol 2016, 8:a019521.
9. Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, et al: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. Leukemia 2019, 33:2628-2639.
10. Sunami Y, Araki M, Kan S, Ito A, Hironaka Y, Imai M, Morishita S, Ohsaka A, Komatsu N: Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. J Biol Chem 2017, 292:2815-2829.
11. Benton CB, Fiskus W, Bhalla KN: Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer. Cancer J 2017, 23:286-291.
12. Yang X, Lu B, Sun X, Han C, Fu C, Xu K, Wang M, Li D, Chen Z, Opal P, et al: ANP32A regulates histone H3 acetylation and promotes leukemogenesis. Leukemia 2018, 32:1587-1597.
13. Huang S, Huang Z, Ma C, Luo L, Li YF, Wu YL, Ren Y, Feng C: Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia. Ann Transl Med 2020, 8:345.
14. Sun X, Lu B, Han C, Qiu W, Jin Q, Li D, Li Q, Yang Q, Wen Q, Opal P, et al: ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia. Blood Cancer J 2017, 7:661.
15. Schneider R, Bannister AJ, Weise C, Kouzarides T: Direct binding of INHAT to H3 tails disrupted by modifications. J Biol Chem 2004, 279:23859-23862.
16. Seo SB, Macfarlan T, McNamara P, Hong R, Mukai Y, Heo S, Chakravarti D: Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. J Biol Chem 2002, 277:14005-14010.
17. Kobe B, Kajava AV: The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 2001, 11:725-732.
18. Zia S, Batool S, Shahid R: Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis. Med Hypotheses 2020, 136:109513.
19. Yu C, Zeng J, Yan Z, Ma Z, Liu S, Huang Z: Baicalein antagonizes acute megakaryoblastic leukemia in vitro and in vivo by inducing cell cycle arrest. Cell Biosci 2016, 6:20.
20. Liu T, Zhang Z, Yu C, Zeng C, Xu X, Wu G, Huang Z, Li W: Tetrandrine antagonizes acute megakaryoblastic leukaemia growth by forcing autophagy-mediated differentiation. Br J Pharmacol 2017, 174:4308-4328.
21. Liu T, Guo Q, Guo H, Hou S, Li J, Wang H: Quantitative analysis of histone H3 and H4 post-translational modifications in doxorubicin-resistant leukemia cells. Biomed Chromatogr 2016, 30:638-644.
22. Boileau M, Shirinian M, Gayden T, Harutyunyan AS, Chen CCL, Mikael LG, Duncan HM, Neumann AL, Arreba-Tutusaus P, De Jay N, et al: Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness. Nat Commun 2019, 10:2891.
23. Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, et al: Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res 2017, 77:1753-1762.
24. Bewersdorf JP, Shallis R, Stahl M, Zeidan AM: Epigenetic therapy combinations in acute myeloid leukemia: what are the options? Ther Adv Hematol 2019, 10:2040620718816698.
25. Simo-Riudalbas L, Esteller M: Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol 2015, 172:2716-2732.
26. Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, Kahatt C, Raffoux E, Stathis A, Thieblemont C, et al: Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. Clin Pharmacokinet 2016, 55:397-405.
27. Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, et al: Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol 2016, 3:e186-195.
28. Kadota S, Nagata K: pp32, an INHAT component, is a transcription machinery recruiter for maximal induction of IFN-stimulated genes. J Cell Sci 2011, 124:892-899.
29. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D: Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 2001, 104:119-130.
30. Velmurugan BK, Yeh KT, Lee CH, Lin SH, Chin MC, Chiang SL, Wang ZH, Hua CH, Tsai MH, Chang JG, Ko YC: Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) association with lymph node metastasis predicts poor survival in oral squamous cell carcinoma patients. Oncotarget 2016, 7:10879-10890.
31. Yan W, Bai Z, Wang J, Li X, Chi B, Chen X: ANP32A modulates cell growth by regulating p38 and Akt activity in colorectal cancer. Oncol Rep 2017, 38:1605-1612.
32. Tian Z, Liu Z, Fang X, Cao K, Zhang B, Wu R, Wen X, Wen Q, Shi H, Wang R: ANP32A promotes the proliferation, migration and invasion of hepatocellular carcinoma by modulating the HMGA1/STAT3 pathway. Carcinogenesis 2021, 42:493-506.
33. Wang M, Tang L, Liu D, Ying QL, Ye S: The transcription factor Gbx2 induces expression of Kruppel-like factor 4 to maintain and induce naive pluripotency of embryonic stem cells. J Biol Chem 2017, 292:17121-17128.
34. Wang M, Zhang T, Zhang X, Jiang Z, Peng M, Huang Z: BMP2K dysregulation promotes abnormal megakaryopoiesis in acute megakaryoblastic leukemia. Cell Biosci 2020, 10:57.
35. Ziv-Av A, Giladi ND, Lee HK, Cazacu S, Finniss S, Xiang C, Pauker MH, Barda-Saad M, Poisson L, Brodie C: RTVP-1 regulates glioma cell migration and invasion via interaction with N-WASP and hnRNPK. Oncotarget 2015, 6:19826-19840.
36. Huang ZL, Gao M, Ji MS, Tao K, Xiao Q, Zhong L, Zeng JM, Feng WL: TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization. Amino Acids 2013, 44:461-472.
37. Yan FJ, Fan J, Huang Z, Zhang JJ: ZNF300 tight self-regulation and functioning through DNA methylation and histone acetylation. Cell Biosci 2017, 7:33.
38. Yu C, Yang Q, Chen Y, Wang D, Levine R, Crispino J, Wen Q, Huang Z: Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms. Cell Biosci 2016, 6:34.